Current Report Filing (8-k)
February 28 2018 - 5:25PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date
of report (Date of earliest event reported): February 27, 2018
Applied
DNA Sciences, Inc.
(Exact
Name of Registrant as Specified in Charter)
Delaware
(State
or Other Jurisdiction
of
Incorporation)
|
001-36745
(Commission
File Number)
|
59-2262718
(IRS
Employer
Identification
No.)
|
50
Health Sciences Drive
Stony
Brook, New York 11790
(Address
of Principal Executive Offices) (Zip Code)
631-240-
8800
(Registrant’s
telephone number, including area code)
Not
Applicable
(Former
Name or Former Address, if Changed Since Last Report)
Check the appropriate
box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2 below):
|
¨
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company
¨
If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act.
¨
Item 5.07. Submission
of Matters to a Vote of Security Holders.
On
February 27, 2018, the Company held its Annual Meeting of Stockholders (the “Annual Meeting”). The following proposals
were voted on and approved by the Company’s stockholders at the Annual Meeting with the stockholders having voted as set
forth below:
Proposal
1 - to elect our board of directors, consisting of James A. Hayward, John Bitzer, III, Robert B. Catell, Joseph D. Ceccoli, Charles
S. Ryan, Yacov A. Shamash, Sanford R. Simon, and Elizabeth Schmalz Ferguson, each for a one-year term or until their successors
are duly elected and qualified:
Directors
|
|
For
|
|
Withheld
|
|
James A. Hayward
|
|
9,747,350
|
|
197,433
|
|
|
John Bitzer, III
|
|
8,864,777
|
|
1,080,006
|
|
|
Robert B. Catell
|
|
9,673,874
|
|
270,909
|
|
|
Joseph D. Ceccoli
|
|
9,788,814
|
|
155,969
|
|
|
Charles S. Ryan
|
|
9,799,322
|
|
145,461
|
|
|
Yacov A. Shamash
|
|
9,795,888
|
|
148,895
|
|
|
Elizabeth Schmalz Ferguson
|
|
9,799,127
|
|
145,656
|
|
|
Sanford R. Simon
|
|
9,792,576
|
|
152,207
|
|
Broker Non-Vote for each director 12,589,784
Proposal 2 - to ratify
the appointment of Marcum LLP as our independent registered public accounting firm for the fiscal year ending September 30, 2018:
For
|
|
Against
|
|
Abstain
|
22,186,531
|
|
141,499
|
|
206,537
|
Broker Non-Vote – 0
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
|
Applied DNA Sciences, Inc.
|
|
|
(Registrant)
|
|
|
|
|
|
|
|
|
/s/ James A. Hayward
|
|
|
James A. Hayward
Chief Executive Officer
|
Date: February 28, 2018
|
|
|
|
Applied DNA Sciences (NASDAQ:APDN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Applied DNA Sciences (NASDAQ:APDN)
Historical Stock Chart
From Sep 2023 to Sep 2024